BioGaia ABBGLAF 100 Days Payable is 49.01 as of Mar. 2026, which is 1% above its 10-year median of 48.60. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, BioGaia AB ranks worse than 78.8% on this metric.
BioGaia AB's average Accounts Payable for the
three
months ended in Mar. 2026 was $6.1 Mil. BioGaia AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $11.4 Mil.
Hence, BioGaia AB's Days Payable for the
three
months ended in Mar. 2026 was 49.01.
The historical rank and industry rank for BioGaia AB's Days Payable or its related term are showing as below:
BGLAF'
s Days Payable Range Over the Past 10 Years
Min: 42.87 Med: 48.6 Max: 81.57
Current: 45.89
During the past 13 years, BioGaia AB's highest Days Payable was 81.57. The lowest was 42.87. And the median was 48.60.
BGLAF's Days Payable is ranked worse than 78.8% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs BGLAF: 45.89
BioGaia AB's Days Payable
increased
from Mar. 2025 (41.53) to Mar. 2026 (49.01).
It may suggest that BioGaia ABdelayed paying its suppliers.
BioGaia AB Days Payable Related Terms
BioGaia AB Days Payable Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Days Payable distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioGaia AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Days Payable of 49.01 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioGaia AB and its competitors. This is near median its historical median of 48.60. Over the past decade, BioGaia AB's Days Payable has ranged from 42.87 to 81.57. According to the industry distribution chart, BioGaia AB ranks #725 out of 920 companies in the Drug Manufacturers industry, placing it in the top 78.8%.
Is BioGaia AB's Days Payable too high?
BioGaia AB's current Days Payable of 49.01 is near median its 10-year median of 48.60. Over the past 10 years, this metric has ranged from a low of 42.87 to a high of 81.57. The Drug Manufacturers industry median Days Payable is 90.84. BioGaia AB's value of 49.01 is 46% below this industry median. Based on the distribution chart, BioGaia AB ranks #725 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #725 out of 920 companies for Days Payable. This places BioGaia AB in the lower half of its industry. The industry median Days Payable is 90.84. BioGaia AB's value of 49.01 is 46% below this benchmark. Historically, BioGaia AB's own Days Payable has ranged from 42.87 to 81.57 over the past decade. While the company's 10-year median is 48.60 vs. the industry median of 90.84, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Days Payable of 49.01 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Days Payable is 49.01, which is near median its own 10-year median of 48.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Days Payable of 49.01. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Days Payable is 49.01, which is near median its 10-year median of 48.60 and 46% below the Drug Manufacturers industry median of 90.84. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Days Payable is 49.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Days Payable: 49.01 (near median its 10-year median of 48.60)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 46% below the Drug Manufacturers median (#725 of 920)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
